Fig. 3: Tumor cells are a source of NOS3 in human prostate cancer.
From: S-nitrosylation of CSF1 receptor increases the efficacy of CSF1R blockage against prostate cancer
A, B Representative multiplexed fluorescence staining images of tumor tissue from one prostate biopsy patient stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue) and antibodies against FOXM1 (red) and NOS3/CSF1 (green). Percentage of FOXM1 + prostate cancer cells that are also NOS3 + as well as CSF1 + in prostate adenocarcinomas (n = 3) from the patients listed in Table S1. Data are means ± SEM of three images per tumor area for each patient. Scale bar, 22 μm. C BH4 concentration was estimated using a competitive enzyme-linked immunosorbent assay (ELISA) using prostate biopsy lysates (n = 3). **p < 0.01. Scale bar, 22 μm. D Uncoupling of NOS3 as shown by dimers using prostate biopsies from different Gleason grades. The lysates were run at low temperatures without beta-mercaptoethanol to look for dimers. E GSNOR activity was measured and recorded at 340 nm for 10 minutes in prostate biopsies from Gleason grade 6 and Gleason grade 9 (n = 3). F Representative immunofluorescent images for patient biopsies (Gleason grade 6 and 9) stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue), and Cysteine sulfinic acid (red). Scale bar 100 μm.
